Skip to content

Journal · Immunology · Updated 15 November 2026

Nature Immunology

Read Nature Immunology research on DeepDyve. No university library needed.

Nature Immunology, part of Springer Nature’s Nature Portfolio, has published research on the immune system since 2000, covering how immune cells develop, respond and go wrong in infection, cancer and autoimmune disease. Its papers range from T cell biology and tumor immunity to conditions such as rheumatoid arthritis and celiac disease. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.

Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.

Personal plans aren’t for business use. Reading for work? See Enterprise.

Cover of Nature Immunology
November 2026 issue

Nature Immunology at a glance

Full title
Nature Immunology
Abbreviation (NLM)
Nat Immunol
Publisher
Springer Nature (Nature Portfolio)
Print ISSN
1529-2908
Online ISSN (eISSN)
1529-2916
First published
2000
Subjects
Allergy and Immunology
Access model
Hybrid: subscription, with an open access option
On DeepDyve
Research articles; availability varies by article

Ways to access Nature Immunology

28% of the articles Nature Immunology published from January 1 to November 14, 2026 are open access and free to read. For the rest, look for a preprint or the authors’ manuscript, check a library, or read them on DeepDyve.

  1. Open access articles. 28% of Nature Immunology articles published from January 1 to November 14, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
  2. Preprints. Nature Immunology encourages authors to post preprints of their research on servers such as arXiv or bioRxiv. A preprint can differ from the published paper.
  3. The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors make their accepted manuscript public 6 months after publication, on a personal website or in a repository such as PubMed Central.
  4. NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
  5. A library. Your university, hospital or public library may subscribe to Nature Immunology. Check its journal list and whether it offers remote access.
  6. DeepDyve. Read Nature Immunology articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.

Sources: Springer Nature self-archiving policy; Nature Portfolio preprint policy; NIH Public Access Policy; open access share from Crossref license data.

Impact factor and metrics

Nature Immunology’s 2025 Journal Impact Factor is 26.5, and its 5-year Impact Factor is 29.1.

26.5

Journal Impact Factor (2025)

29.1

5-year Impact Factor (2025)

11.131

SCImago Journal Rank (2025)

5 days

Median time to first editorial decision

180 days

Median time from submission to acceptance

28%

Articles published open access, Jan 1 to Nov 14, 2026

Source: Springer Nature journal metrics for Nature Immunology. Impact Factor from Clarivate Journal Citation Reports. Open access share: 83 of 297 articles published January 1 to November 14, 2026 carry a Creative Commons license, per Crossref.

Recent Nature Immunology research worth reading

Published May to September 2026. Summaries describe what the authors report.

  1. LitStreamImmunology · Cancer immunotherapy

    Intratumoral T cell activation kills tumors regardless of T cell specificity

    The authors show that activating unexhausted bystander T cells inside tumors cleared melanoma in mice without any tumor-specific T cells, with interferon-γ, tumor necrosis factor and nitric oxide inducing caspase-dependent death, and report that gene signatures of this response predicted survival in human patients with melanoma.

    Nature Immunology, September 2026 · DOI 10.1038/s41590-026-02642-z

  2. LitStreamImmunology · Rheumatoid arthritis

    Immune-mediated rheumatoid arthritis: from single-cell genomics to new therapies

    In this Perspective, the author discusses how spatial transcriptomics, ex vivo mechanistic and organoid studies, and better use of animal models can build on largely descriptive single-cell genomics data to explain how immune-mediated arthritis develops, with a focus on rheumatoid arthritis.

    Ivashkiv · Nature Immunology, published online August 31, 2026 · DOI 10.1038/s41590-026-02639-8

  3. LitStreamImmunology · T cell differentiation

    The dual role of TOX in regulating TH1 and CD8+ T cell fate

    This commentary notes that chronic antigen exposure drives TOX expression in CD8+ T cells and is associated with an exhausted, hypofunctional state, whereas new data show that TOX in CD4+ T cells defines the TH1 lineage and supports the effector function of those cells.

    Nature Immunology, May 2026 · DOI 10.1038/s41590-026-02494-7

  4. LitStreamImmunology · T cell differentiation

    TOX drives CD4+ TH1 effector function, antitumor immunity and autoimmune pathology

    Using gain-of-function and loss-of-function studies, the authors show that TOX is critical for CD4+ TH1 cell differentiation and interferon-γ production, and that TOX expression in CD4+ T cells was associated with antitumor immunity and improved immunotherapy responses as well as pathogenic autoimmune responses.

    Nature Immunology, May 2026 · DOI 10.1038/s41590-026-02453-2

  5. Open accessImmunology · Celiac disease

    The long noncoding RNA lnc13 restrains inflammatory responses to maintain oral tolerance to gluten

    The authors identified the long noncoding RNA lnc13 in a screen and report that HLA-DQ8 transgenic mice lacking it showed hallmark features of lost oral tolerance after eating gluten, including more IFN-γ+ lymphocytes and crypt hyperplasia, and that lnc13 limits immune cell responsiveness to proinflammatory signals.

    Nature Immunology, June 2026 · DOI 10.1038/s41590-026-02506-6

See every Nature Immunology article on DeepDyve

Questions about Nature Immunology

How can I read Nature Immunology articles without a subscription?

28% of Nature Immunology articles published from January 1 to November 14, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors make their accepted manuscript public 6 months after publication, on a personal website or in a repository such as PubMed Central. Your library may also subscribe. DeepDyve lets you read Nature Immunology articles online for $59 a month or $499 a year after a free first month.

What is the abbreviation for Nature Immunology?

Nature Immunology’s NLM (PubMed) abbreviation is Nat Immunol.

What is the ISSN of Nature Immunology?

The print ISSN is 1529-2908 and the online ISSN is 1529-2916.

Is Nature Immunology open access?

Nature Immunology is a hybrid journal: most articles are published under the subscription model, and authors can choose to publish open access. From January 1 to November 14, 2026, 83 of 297 Nature Immunology articles (28%) carry a Creative Commons license, per Crossref.

What is the impact factor of Nature Immunology?

Nature Immunology’s Journal Impact Factor is 26.5 (2025), and its 5-year Impact Factor is 29.1, according to Springer Nature’s published metrics.

Nature Immunology articles on DeepDyve are licensed from Springer Nature. Journal facts as of 15 November 2026.

Start reading Nature Immunology today

One month free, then less than $2 a day. Nature Immunology, plus millions of articles from thousands of journals.

Start free month

Like this: